Your monthly Enhertu cost savings if eligible
With our assistance, you could access the Enhertu patient assistance program and obtain your medication for free. We only charge a flat monthly fee of $49 per medication for our services.
Am I eligible for Enhertu patient assistance?
We review each Enhertu enrollment application individually to determine if you are eligible. Each assistance program has its own eligibility criteria and the factors considered by most programs are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for the Enhertu patient assistance program?
Our process makes it as easy as possible to apply for the Enhertu patient assistance program. Begin by completing the enrollment application form on our website. Tell us about any medications that you are taking, including Enhertu, your healthcare provider, your insurance plan, and your household income. This information is required by the pharmaceutical manufacturers who will supply the medication, so it is important to make sure this information is accurate and up to date.
We will review the information that you have provided to determine whether you are eligible for patient assistance. If we can pre-qualify you for assistance, NiceRx will handle the full enrollment process on your behalf. If you are approved by the pharmaceutical company, you will typically start receiving your medication in 6 – 8 weeks.
Is NiceRx an Enhertu coupon provider?
NiceRx is not an Enhertu coupon, Enhertu discount card, or Enhertu copay card provider. We do not offer Enhertu manufacturer coupons, Enhertu discounts, rebates, Enhertu savings cards, trial offers, or free Enhertu samples. We are a service provider that helps eligible individuals access their medication directly from the U.S. pharmaceutical company.
Can NiceRx help me get Enhertu cheaper if I have insurance?
NiceRx may be able to help you if:
- You have a high copay or coinsurance responsibility for Enhertu
- Your insurance company will not pay for your Enhertu prescription
- Your healthcare plan does not cover your medication
- You do not have insurance
Please apply online to find out if we can help you.
How much does Enhertu cost without insurance?
Without insurance, Enhertu costs will vary depending on where you buy the medication as prices will vary by retailer. As a guide, Enhertu intravenous powder for injection 100 mg will cost around $2,560 for 1 powder for injection.
How much does Enhertu cost with insurance?
The copay for Enhertu will depend on the terms of your healthcare plan. Your healthcare provider or pharmacist will be able to calculate your copay with your current insurance. Contact them to find out more.
What is Enhertu?
Enhertu is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Daiichi Sankyo, Inc. and AstraZeneca. Enhertu is a HER2 (human epidermal growth factor receptor 2)-directed monoclonal antibody drug conjugate (ADC) indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This indication is approved under accelerated approval based on tumor response rate and duration of response.
Some breast cancer cells may overexpress a particular gene known as HER2. The HER2 gene makes a protein known as a HER2 receptor. These HER2 receptors receive signals that stimulate the cell to grow and multiply. Breast cancer cells with too many HER2 receptors can pick up too many growth signals and grow and multiply too fast. Breast cancer cells that overexpress the HER2 gene are said to be HER2-positive.
Results from the pivotal Destiny-Breast04 Phase III trial showed Enhertu (trastuzumab deruxtecan) demonstrated an improvement in both progression-free survival (PFS) and overall survival (OS) in patients with HER2-low unresectable and/or metastatic breast cancer regardless of hormone receptor (HR) status versus physician’s choice of chemotherapy.
Enhertu is also used for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
What doses of Enhertu are available?
Enhertu is available in injection form, in the following doses: 100 mg lyophilized powder in a single-dose vial.
Do not substitute Enhertu for or with trastuzumab or ado-trastuzumab emtansine. The recommended dosage of Enhertu for breast cancer is 5.4 mg/kg given as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity. The recommended dosage for gastric cancer is 6.4 mg/kg given as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity.
Please see the full prescribing information for the complete boxed warning and patient safety information. Always speak with a healthcare professional about any changes to your dose so they can monitor and evaluate your condition.
Enhertu active ingredients
The active ingredient of Enhertu is trastuzumab deruxtecan (fam-trastuzumab-deruxtecan-nxki), a topoisomerase I inhibitor chemotherapy called DXd. Topoisomerase I inhibitors work by interfering with the cancer cell’s ability to replicate. This type of chemotherapy is not typically used to treat HER2-positive breast cancers, so researchers believe it is less likely that the cancers will develop resistance to it.
Enhertu is an antibody-drug conjugate targeted therapy. The combination of the topoisomerase I inhibitor and the linking compound is called deruxtecan. The linking compound attaches the fam-trastuzumab to the topoisomerase I inhibitor chemotherapy.
Enhertu side effects
The most common side effects of Enhertu in clinical trials include:
- Nausea, vomiting
- Constipation, diarrhea, decreased appetite
- Leukopenia (reduced white blood cells)
- Neutropenia – monitor complete blood
- Platelet count decreased
In rare instances, Enhertu can cause more serious side effects. These can include:
- Interstitial lung disease (ILD) and pneumonitis
- Left ventricular dysfunction – assess LVEF prior to initiation of treatment and at regular intervals during treatment. Permanently discontinue Enhertu in patients with symptomatic congestive heart failure
Your doctor will assess the benefits of using Enhertu against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Enhertu to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Enhertu drug interactions
Enhertu can interact with other medications. These include:
- Antipsychotics – clozapine
- DMARDs – leflunomide, teriflunomide
- Immunosuppressants – fingolimod, ozanimod, siponimod
This list is not exhaustive and other prescription drugs may interact with Enhertu.
You should not use Enhertu if you:
- Are allergic to the active ingredient trastuzumab deruxtecan
- Are allergic to any of the other ingredients in Enhertu
- Have heart problems
- Have breathing problems
- Have an infection
- Are pregnant or are planning to become pregnant – use effective contraception during treatment and for at least 7 months after the last dose
- Are breastfeeding or are planning to breastfeed – do not breastfeed while using this medicine, and for at least 7 months after your last dose
Talk to your doctor before using Enhertu if you:
- Are taking any of the medications that could interact with Enhertu
Enhertu is the trademark brand name for trastuzumab deruxtecan manufactured by Daiichi Sankyo, Inc. and AstraZeneca. A generic version of trastuzumab deruxtecan is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Enhertu savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.